Collaboration, License, and Other Agreements - North America - General Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) item $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaboration, License, Promotion and Other Commercial Agreements
Research and development expense	$ 111,421	$ 116,085	$ 44,265
AbbVie Plc
Collaboration, License, Promotion and Other Commercial Agreements
Remaining commercial-period performance obligations | item	3
Cost sharing amount, reduction to research and development	$ 8,600	11,600	8,900
Collaborative arrangement, percentage of obligation of development costs incurred	50.00%
Percentage of net profit from commercialization (as a percent)	50.00%
Percentage of net loss from commercialization (as a percent)	50.00%
North America
Collaboration, License, Promotion and Other Commercial Agreements
Research and development expense	$ 7,400	$ 7,000	$ 8,000
North America | AbbVie Plc | Collaborative arrangements, LINZESS
Collaboration, License, Promotion and Other Commercial Agreements
Revenue, reduction	$ 43,000
Net income per share, excluding collaborative arrangements revenue reduction - basic (in dollars per share) | $ / shares	$ 0.21
Net income per share, excluding collaborative arrangements revenue reduction - diluted (in dollars per share) | $ / shares	$ 0.19